Understanding HIV: How It Affects the Immune System

Virology & Target

HIV-1 (global) and HIV-2 (West Africa) are lentiviruses. Primary target: CD4+ T-helper cells (also macrophages, dendritic cells).

Transmission

  • Sexual (vaginal, anal, oral)
  • Blood: sharing needles, transfusions (rare now), occupational exposure
  • Vertical: pregnancy, delivery, breastfeeding

Stages of Infection

StageFeatures
Acute (2–4 weeks post-exposure)High viremia; flu-like syndrome (fever, rash, lymphadenopathy); high transmission risk
Clinical latency (chronic)Years; low-level replication; CD4 decline ~50–100 cells/µL/yr; often asymptomatic
AIDSCD4 <200 or AIDS-defining illness (OIs, malignancies); severe immune deficiency

Complications (AIDS-Defining)

  • Pneumocystis pneumonia (PCP)
  • Cryptococcal meningitis
  • Toxoplasma encephalitis
  • Mycobacterium avium complex (MAC)
  • Cytomegalovirus (CMV) retinitis
  • Kaposi sarcoma, non-Hodgkin lymphoma, invasive cervical cancer

Treatment: Antiretroviral Therapy (ART)

  • Combination of ≥3 drugs from ≥2 classes (INSTI + 2 NRTIs preferred first-line).
  • Goal: Viral suppression (<50 copies/mL), CD4 recovery, normal lifespan.
  • U=U: Undetectable = Untransmittable (sexual transmission).

Prevention

  • Condoms, PrEP (tenofovir/emtricitabine), PEP (post-exposure), syringe services, treatment as prevention, safe blood supply.

Early diagnosis and sustained ART transform HIV into a manageable chronic condition.

HIV & AIDS - Related Articles